CNXC vs. ARCT
CNXC (Concentrix Corporation) and ARCT (Arcturus Therapeutics Holdings Inc.) are both stocks. CNXC operates in Information Technology Services (Technology), while ARCT operates in Biotechnology (Healthcare). Over the past 5 years, CNXC returned -29.42%/yr vs -27.07%/yr for ARCT. At a 0.25 correlation, their price movements are largely independent.
Performance
CNXC vs. ARCT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CNXC achieves a -40.11% return, which is significantly lower than ARCT's 15.50% return.
CNXC
- 1D
- 1.71%
- 1M
- -7.59%
- YTD
- -40.11%
- 6M
- -38.07%
- 1Y
- -51.26%
- 3Y*
- -31.46%
- 5Y*
- -29.42%
- 10Y*
- —
ARCT
- 1D
- -2.07%
- 1M
- 0.71%
- YTD
- 15.50%
- 6M
- 10.11%
- 1Y
- -43.41%
- 3Y*
- -33.38%
- 5Y*
- -27.07%
- 10Y*
- —
CNXC vs. ARCT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
CNXC Concentrix Corporation | -40.11% | -1.39% | -55.03% | -25.36% | -24.91% | 81.22% | 23.37% |
ARCT Arcturus Therapeutics Holdings Inc. | 15.50% | -63.88% | -46.18% | 85.91% | -54.17% | -14.68% | -29.24% |
Correlation
The correlation between CNXC and ARCT is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.26 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.26 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since Nov 24, 2020 | 0.25 |
Fundamentals
CNXC:
$1.49B
ARCT:
$201.22M
CNXC:
-$21.33
ARCT:
-$1.81
CNXC:
0.15
ARCT:
4.16
CNXC:
0.54
ARCT:
1.05
CNXC:
$9.95B
ARCT:
$46.80M
CNXC:
$3.27B
ARCT:
$40.72M
CNXC:
-$944.68M
ARCT:
-$84.61M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CNXC vs. ARCT — Risk / Return Rank
CNXC
ARCT
CNXC vs. ARCT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Concentrix Corporation (CNXC) and Arcturus Therapeutics Holdings Inc. (ARCT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CNXC | ARCT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.37 | ||
| Sortino ratioReturn per unit of downside risk | -0.94 | ||
| Omega ratioGain probability vs. loss probability | 0.86 | 0.98 | -0.12 |
| Calmar ratioReturn relative to maximum drawdown | -0.83 | -0.58 | -0.25 |
| Martin ratioReturn relative to average drawdown | -1.32 | -0.79 | -0.53 |
Loading charts...
Drawdowns
CNXC vs. ARCT - Drawdown Comparison
The maximum CNXC drawdown since its inception was -87.86%, smaller than the maximum ARCT drawdown of -95.23%. Use the drawdown chart below to compare losses from any high point for CNXC and ARCT.
Loading charts...
Drawdown Indicators
| CNXC | ARCT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.86% | -95.23% | +7.37% |
Max Drawdown (1Y)Largest decline over 1 year | -61.71% | -74.53% | +12.82% |
Max Drawdown (3Y)Largest decline over 3 years | -76.50% | -86.71% | +10.21% |
Max Drawdown (5Y)Largest decline over 5 years | -87.86% | -89.87% | +2.01% |
Current DrawdownCurrent decline from peak | -87.10% | -94.27% | +7.17% |
Average DrawdownAverage peak-to-trough decline | -47.90% | -73.11% | +25.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 38.98% | 55.02% | -16.04% |
Volatility
CNXC vs. ARCT - Volatility Comparison
The current volatility for Concentrix Corporation (CNXC) is 15.55%, while Arcturus Therapeutics Holdings Inc. (ARCT) has a volatility of 17.02%. This indicates that CNXC experiences smaller price fluctuations and is considered to be less risky than ARCT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CNXC | ARCT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.55% | 17.02% | -1.47% |
Volatility (6M)Calculated over the trailing 6-month period | 52.51% | 39.81% | +12.70% |
Volatility (1Y)Calculated over the trailing 1-year period | 61.12% | 92.63% | -31.51% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 48.36% | 91.79% | -43.43% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 49.73% | 101.97% | -52.24% |
Dividends
CNXC vs. ARCT - Dividend Comparison
CNXC's dividend yield for the trailing twelve months is around 5.80%, while ARCT has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
ARCT Arcturus Therapeutics Holdings Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
CNXC Concentrix Corporation | 5.80% | 3.27% | 2.87% | 1.15% | 0.77% | 0.14% |
Financials
CNXC vs. ARCT - Financials Comparison
This section allows you to compare key financial metrics between Concentrix Corporation and Arcturus Therapeutics Holdings Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CNXC and ARCT have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ARCT has higher volatility (17.02%) compared to CNXC (15.55%). In terms of maximum drawdown, CNXC dropped -87.86% vs ARCT's -95.23%.
ARCT currently has the higher Sharpe Ratio (-0.47 vs -0.84), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CNXC and ARCT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer